Cargando…

l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease

l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson’s disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine. In contrast to this generally accepted idea, l-DOPA i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goshima, Yoshio, Masukawa, Daiki, Kasahara, Yuka, Hashimoto, Tatsuo, Aladeokin, Aderemi Caleb
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785630/ https://www.ncbi.nlm.nih.gov/pubmed/31632270 http://dx.doi.org/10.3389/fphar.2019.01119

Ejemplares similares

Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
por: Schintu, Nicoletta, et al.
Publicado: (2020)

Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson’s Disease
por: dos Santos Pereira, Maurício, et al.
Publicado: (2021)

Antioxidants Attenuate Isolation- and L-DOPA-Induced Aggression in Mice
por: Hira, Sundas, et al.
Publicado: (2018)

High performance microbiological transformation of L-tyrosine to L-dopa by Yarrowia lipolytica NRRL-143
por: Ali, Sikander, et al.
Publicado: (2007)

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats
por: Wang, Wen-Wen, et al.
Publicado: (2019)

The therapeutic potential of orphan GPCRs, GPR35 and GPR55
por: Shore, Derek M., et al.
Publicado: (2015)

Pan-Cancer Analysis and Drug Formulation for GPR139 and GPR142
por: Kaushik, Aman Chandra, et al.
Publicado: (2021)

GPR143 mutations in Chinese patients with ocular albinism type 1
por: Jia, Xiuhua, et al.
Publicado: (2017)

Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1
por: Smith, Nicola J.
Publicado: (2015)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

Molecular Effects of L-dopa Therapy in Parkinson’s Disease
por: Dorszewska, Jolanta, et al.
Publicado: (2014)

Beyond L-DOPA: hope for Parkinson’s treatment and diagnosis
Publicado: (2017)

Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model
por: dos Santos Pereira, Maurício, et al.
Publicado: (2022)

Advances in Neurobiology and Pharmacology of GPR12
por: Allende, Gonzalo, et al.
Publicado: (2020)

3-OBA Is Not an Antagonist of GPR81
por: Mohammad Nezhady, Mohammad Ali, et al.
Publicado: (2022)

Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55
por: Guerrero-Alba, Raquel, et al.
Publicado: (2019)

Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson’s Disease and Dopa-Responsive Dystonia
por: Kawahata, Ichiro, et al.
Publicado: (2020)

Deep intronic GPR143 mutation in a Japanese family with ocular albinism
por: Naruto, Takuya, et al.
Publicado: (2015)

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
por: Stefano, George B., et al.
Publicado: (2012)

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
por: Chagraoui, Abdeslam, et al.
Publicado: (2019)

GPR143 Gene Mutations in Five Chinese Families with X-linked Congenital Nystagmus
por: Han, Ruifang, et al.
Publicado: (2015)

Simultaneous Expression of ABCA4 and GPR143 Mutations: A Complex Phenotypic Manifestation
por: Lee, Winston, et al.
Publicado: (2016)

L-DOPA
por: Hornykiewicz, Oleh
Publicado: (2017)

Altered cerebellar connectivity in Parkinson's patients ON and OFF L-DOPA medication
por: Festini, Sara B., et al.
Publicado: (2015)

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
por: Hoon, Monique, et al.
Publicado: (2017)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
por: Bello, Fabio Del, et al.
Publicado: (2019)

Δ(9)-THC and N-arachidonoyl glycine regulate BV-2 microglial morphology and cytokine release plasticity: implications for signaling at GPR18
por: McHugh, Douglas, et al.
Publicado: (2014)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

HIF-1α in Osteoarthritis: From Pathogenesis to Therapeutic Implications
por: Zeng, Chu-Yang, et al.
Publicado: (2022)

A CYPome-wide study reveals new potential players in the pathogenesis of Parkinson’s disease
por: Hartz, Philip, et al.
Publicado: (2023)

Dopa Responsive Slow Orthostatic Tremor in Parkinson’s Disease
por: Lee, Suk Yoon, et al.
Publicado: (2011)

Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
por: Athulya, RT, et al.
Publicado: (2020)

Excessive Sensitivity to Uncertain Visual Input in L-DOPA-Induced Dyskinesias in Parkinson’s Disease: Further Implications for Cerebellar Involvement
por: Stevenson, James K. R., et al.
Publicado: (2014)

Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients
por: Bedarf, J. R., et al.
Publicado: (2017)

L-Dopa and Behavior
por: Kebabian, John
Publicado: (1974)

CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation
por: Zhou, Juan, et al.
Publicado: (2016)

Readiness Potential in Parkinson's Disease: Effects of L-Dopa Therapy and Brain Transplants
por: Martínez, D. N. Velázquez, et al.
Publicado: (1992)

The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment
por: Managò, Francesca, et al.
Publicado: (2012)

L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson’s Disease
por: Blosser, Joshua A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5otpive485vseci3koo9qv2is2